Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Takeharu Kunieda"'
Autor:
Akihiro Inoue, Takanori Ohnishi, Masahiro Nishikawa, Yoshihiro Ohtsuka, Kosuke Kusakabe, Hajime Yano, Junya Tanaka, Takeharu Kunieda
Publikováno v:
Cancers, Vol 15, Iss 19, p 4898 (2023)
High invasiveness is a characteristic of glioblastoma (GBM), making radical resection almost impossible, and thus, resulting in a tumor with inevitable recurrence. GBM recurrence may be caused by glioma stem-like cells (GSCs) that survive many kinds
Externí odkaz:
https://doaj.org/article/2f9c94b08f5645af84e78cb3155f3ef8
Autor:
Akihiro Inoue, Takanori Ohnishi, Masahiro Nishikawa, Hideaki Watanabe, Kosuke Kusakabe, Mashio Taniwaki, Hajime Yano, Yoshihiro Ohtsuka, Shirabe Matsumoto, Satoshi Suehiro, Daisuke Yamashita, Seiji Shigekawa, Hisaaki Takahashi, Riko Kitazawa, Junya Tanaka, Takeharu Kunieda
Publikováno v:
Biomedicines, Vol 11, Iss 9, p 2369 (2023)
Recurrent glioblastoma multiforme (GBM) is largely attributed to peritumoral infiltration of tumor cells. As higher CD44 expression in the tumor periphery correlates with higher risk of GBM invasion, the present study analyzed the relationship betwee
Externí odkaz:
https://doaj.org/article/44706f2a476847e3abcc2f9a4dfed5f5
Autor:
Masahiro Nishikawa, Akihiro Inoue, Takanori Ohnishi, Hajime Yano, Yonehiro Kanemura, Shohei Kohno, Shiro Ohue, Saya Ozaki, Shirabe Matsumoto, Satoshi Suehiro, Yawara Nakamura, Seiji Shigekawa, Hideaki Watanabe, Riko Kitazawa, Junya Tanaka, Takeharu Kunieda
Publikováno v:
Cancer Medicine, Vol 10, Iss 6, Pp 2013-2025 (2021)
Abstract Antiangiogenic therapy with bevacizumab (Bev), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a common treatment for recurrent glioblastoma (GBM), but its survival benefit is limited. Resistance to Bev is thoug
Externí odkaz:
https://doaj.org/article/c9c9b0ba3246479ab1c5326b3e7cd505
Autor:
Masahiro Nishikawa, Akihiro Inoue, Takanori Ohnishi, Hajime Yano, Saya Ozaki, Yonehiro Kanemura, Satoshi Suehiro, Yoshihiro Ohtsuka, Shohei Kohno, Shiro Ohue, Seiji Shigekawa, Hideaki Watanabe, Riko Kitazawa, Junya Tanaka, Takeharu Kunieda
Publikováno v:
Translational Oncology, Vol 14, Iss 8, Pp 101137- (2021)
The poor prognosis of glioblastoma multiforme (GBM) is primarily due to highly invasive glioma stem-like cells (GSCs) in tumors. Upon GBM recurrence, GSCs with highly invasive and highly migratory activities must assume a less-motile state and prolif
Externí odkaz:
https://doaj.org/article/33c4ef903c5b4700aee894ff74b59436
Autor:
Takanori Ohnishi, Daisuke Yamashita, Akihiro Inoue, Satoshi Suehiro, Shiro Ohue, Takeharu Kunieda
Publikováno v:
Brain Sciences, Vol 12, Iss 5, p 567 (2022)
The effectiveness of carmustine (BCNU) wafers on local recurrence of glioblastoma (GBM) remains contentious. We investigated the accumulating high-dose effects of BCNU released from the wafers on the survival of GBM patients by measuring BCNU concent
Externí odkaz:
https://doaj.org/article/75a5ab9347ad40bf91c4fbf6aabafd3c
Autor:
Yawara Nakamura, Akihiro Inoue, Masahiro Nishikawa, Takanori Ohnishi, Hajime Yano, Yonehiro Kanemura, Yoshihiro Ohtsuka, Saya Ozaki, Kosuke Kusakabe, Satoshi Suehiro, Daisuke Yamashita, Seiji Shigekawa, Hideaki Watanabe, Riko Kitazawa, Junya Tanaka, Takeharu Kunieda
Publikováno v:
Acta Neurochirurgica. 164:3253-3266
Increased extracellular glutamate is known to cause epileptic seizures in patients with glioblastoma (GBM). However, predicting whether the seizure will be refractory is difficult. The present study investigated whether evaluation of the levels of va
Autor:
Shirabe Matsumoto, Seiji Shigekawa, Hideaki Watanabe, Saya Ozaki, Yoshihiro Ohtsuka, Hajime Yano, Akihiro Inoue, Takanori Ohnishi, Riko Kitazawa, Yawara Nakamura, Junya Tanaka, Takeharu Kunieda, Yonehiro Kanemura, Masahiro Nishikawa, Daisuke Yamashita, Satoshi Suehiro
Publikováno v:
World Neurosurgery. 153:e76-e95
Background We previously reported that glioma stemlike cells (GSCs) exist in the area of the tumor periphery showing no gadolinium enhancement on magnetic resonance imaging. In the present work, we analyzed glucose metabolism to investigate whether l
Autor:
Hajime Yano, Hideaki Watanabe, Riko Kitazawa, Akihiro Inoue, Satoshi Suehiro, Saya Ozaki, Shiro Ohue, Masahiro Nishikawa, Shirabe Matsumoto, Takeharu Kunieda, Shohei Kohno, Takanori Ohnishi, Seiji Shigekawa, Yonehiro Kanemura, Junya Tanaka, Yawara Nakamura
Publikováno v:
Cancer Medicine, Vol 10, Iss 6, Pp 2013-2025 (2021)
Cancer Medicine
Cancer Medicine
Antiangiogenic therapy with bevacizumab (Bev), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a common treatment for recurrent glioblastoma (GBM), but its survival benefit is limited. Resistance to Bev is thought to be
Autor:
Kosuke Kusakabe, Akihiro Inoue, Hideaki Watanabe, Yawara Nakamura, Masahiro Nishikawa, Yoshihiro Ohtsuka, Masahiro Ogura, Seiji Shigekawa, Mashio Taniwaki, Riko Kitazawa, Takeharu Kunieda
Publikováno v:
Surgical Neurology International; 2023, Vol. 14, p1-8, 8p
Autor:
Mie Kurata, Saya Ozaki, Shiro Ohue, Hideaki Watanabe, Akihiro Inoue, Riko Kitazawa, Satoshi Suehiro, Shohei Kohno, Takeharu Kunieda, Takanori Ohnishi, Shirabe Matsumoto, Mana Fukushima, Masahiro Nishikawa, Seiji Shigekawa
Publikováno v:
Neurosurgical Review. 44:587-597
Glioblastoma multiforme (GBM) is largely due to glioma stem cells (GSCs) that escape from total resection of gadolinium (Gd)-enhanced tumor on MRI. The aim of this study is to identify the imaging requirements for maximum resection of GBM with infilt